Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023
Danielle Moulia(Centers for Disease Control and Prevention), Evelyn Twentyman(Synaptic Research (United States)), Ruth Link‐Gelles(Centers for Disease Control and Prevention), Amadea Britton, Hannah G. Rosenblum(National Center for Immunization and Respiratory Diseases), Katherine E. Fleming-Dutra(Centers for Disease Control and Prevention), Sarah Meyer, Sara E. Oliver(Centers for Disease Control and Prevention), Monica Godfrey, Megan Wallace(Centers for Disease Control and Prevention), Lauren E. Roper(National Center for Immunization and Respiratory Diseases), Matthew F. Daley(Kaiser Permanente)
Cited by 40
Related Papers
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602
Potential Indirect Effects of the COVID-19 Pandemic on Use of Emergency Departments for Acute Life-Threatening Conditions — United States, January–May 2020
|MMWR Morbidity and Mortality Weekly Report|2020|378
Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021
|Preventing Chronic Disease|2021|370
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
|MMWR Morbidity and Mortality Weekly Report|2021|215